Key Points
- Tempus AI CEO Eric Lefkofsky sold 166,250 shares on May 27 at an average price of $46.70, totaling about $7.76 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- After the transaction, Lefkofsky still directly owned 8.81 million shares valued at about $411.4 million, reducing his stake by 1.85%. Tempus AI stock was also noted as down 1.6% in the session referenced.
- The company recently beat quarterly earnings expectations, reporting -$0.13 EPS versus the expected -$0.21 and revenue of $348.1 million, up 36.1% year over year. Analysts currently rate the stock a Moderate Buy with an average target price of $68.64.
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Eric Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $46.70, for a total value of $7,763,875.00. Following the sale, the chief executive officer directly owned 8,808,533 shares in the company, valued at $411,358,491.10. The trade was a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Tempus AI Stock Down 1.6%
NASDAQ TEM opened at $50.47 on Friday. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The stock's 50 day moving average is $48.73 and its two-hundred day moving average is $58.19. The company has a market capitalization of $9.06 billion, a price-to-earnings ratio of -29.34 and a beta of 3.99. Tempus AI, Inc. has a 1-year low of $41.73 and a 1-year high of $104.32.
Tempus AI (NASDAQ:TEM - Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.08. The company had revenue of $348.12 million for the quarter, compared to the consensus estimate of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The company's quarterly revenue was up 36.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.24) earnings per share. Equities analysts forecast that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research analysts have recently issued reports on TEM shares. Mizuho started coverage on shares of Tempus AI in a research note on Thursday, February 19th. They issued an "outperform" rating and a $100.00 target price for the company. Wall Street Zen cut shares of Tempus AI from a "hold" rating to a "sell" rating in a research note on Saturday, February 28th. Stifel Nicolaus set a $60.00 target price on shares of Tempus AI in a research note on Wednesday, February 25th. BTIG Research cut their target price on shares of Tempus AI from $90.00 to $80.00 and set a "buy" rating for the company in a research note on Friday, May 8th. Finally, HC Wainwright cut their target price on shares of Tempus AI from $95.00 to $64.00 and set a "buy" rating for the company in a research note on Monday, May 11th. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, Tempus AI currently has an average rating of "Moderate Buy" and an average target price of $68.64.
Get Our Latest Stock Report on TEM
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Tempus AI by 1,459.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company's stock worth $8,174,000 after buying an additional 94,783 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Tempus AI by 22.1% during the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company's stock worth $762,032,000 after buying an additional 1,706,837 shares in the last quarter. Hussman Strategic Advisors Inc. acquired a new position in Tempus AI during the 3rd quarter worth $1,695,000. Krane Funds Advisors LLC lifted its holdings in Tempus AI by 218.2% during the 3rd quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company's stock worth $2,427,000 after buying an additional 19,358 shares in the last quarter. Finally, Aberdeen Group plc lifted its holdings in Tempus AI by 64.2% during the 4th quarter. Aberdeen Group plc now owns 263,004 shares of the company's stock worth $15,530,000 after buying an additional 102,878 shares in the last quarter. Institutional investors own 24.22% of the company's stock.
Tempus AI Company Profile
(
Get Free Report)
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
